JPH0810226B2 - Platelet aggregation determining method and device, and aggregation determining tool - Google Patents
Platelet aggregation determining method and device, and aggregation determining toolInfo
- Publication number
- JPH0810226B2 JPH0810226B2 JP1139615A JP13961589A JPH0810226B2 JP H0810226 B2 JPH0810226 B2 JP H0810226B2 JP 1139615 A JP1139615 A JP 1139615A JP 13961589 A JP13961589 A JP 13961589A JP H0810226 B2 JPH0810226 B2 JP H0810226B2
- Authority
- JP
- Japan
- Prior art keywords
- aggregation
- concentration
- platelet
- rate curve
- inducer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000004220 aggregation Methods 0.000 title claims description 161
- 230000002776 aggregation Effects 0.000 title claims description 107
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title claims description 52
- 238000000034 method Methods 0.000 title claims description 16
- 239000000411 inducer Substances 0.000 claims description 42
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- 230000001939 inductive effect Effects 0.000 claims description 32
- 230000004520 agglutination Effects 0.000 claims description 30
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 21
- 230000004931 aggregating effect Effects 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 238000007639 printing Methods 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 230000001133 acceleration Effects 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000010586 diagram Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、血栓性疾患の発症、動脈硬化の治療、予防
等のために、血液から分離された多血小板血漿に、血小
板凝集惹起剤を複数段階に濃度を可変して添加し、それ
ぞれの凝集状態から血小板凝集能を判定する方法及び装
置並びに凝集判定具に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial field of application] The present invention provides a platelet aggregation inducer for platelet-rich plasma separated from blood for the development of thrombotic diseases, treatment and prevention of arteriosclerosis, and the like. The present invention relates to a method and an apparatus and an aggregating device for determining the platelet aggregating ability from each aggregating state by adding the concentration in multiple steps.
「薬理と治療」（ライフ・サイエンス出版（株）、Vo
l.13、No.2、Feb.1985、481〜498頁）には、血小板凝集
測定法及び臨床応用に関する論文が記載されている。即
ち、血小板凝集惹起剤を添加した多血小板血漿の時間経
過に対する凝集率の曲線パターンは、典型的には第５図
に示すように、分類される。つまり、TYPE1は１次凝
集、TYPE2は１次凝集のみで解離緩慢、TYPE3は１次凝集
より２次凝集が低い、TYPE4は１次凝集より２次凝集が
高い、TYPE5は凝集が高度に出現して１、２次の境界が
判別できない状態の場合である。無添加のSPAでは自然
凝集が１〜５分程度に出現している。"Pharmacy and Treatment" (Life Science Publishing Co., Ltd., Vo
l.13, No. 2, Feb. 1985, pp. 481 to 498), a paper on a method for measuring platelet aggregation and clinical application is described. That is, the curve pattern of the agglutination rate over time of the platelet-rich plasma to which the platelet aggregation inducer is added is typically classified as shown in FIG. In other words, TYPE1 is primary aggregation, TYPE2 is only primary aggregation and dissociation is slow, TYPE3 is lower secondary aggregation than primary aggregation, TYPE4 is higher secondary aggregation than primary aggregation, and TYPE5 is highly aggregated. This is the case where the primary and secondary boundaries cannot be distinguished. In non-added SPA, spontaneous aggregation appears in about 1 to 5 minutes.
そして、血小板抑制剤を用いる閉塞性脳血管障害、心
筋硬塞等の治療に際して、被検者に対して血小板凝集惹
起剤を複数段階に濃度を可変して添加し、それぞれがい
ずれのパターンに該当するかを判断したり、或は１次、
２次の最大凝集率を確認することにより、亢進、正常又
は抑制の程度を判定し、治療効果の判定、モニタリング
等を行っていた。Then, in the treatment of obstructive cerebrovascular disorder, myocardial infarction, etc., using a platelet inhibitor, a platelet aggregation inducer is added to a subject while varying the concentration in multiple stages, each of which corresponds to which pattern. Decide whether to do it, or the primary,
By confirming the secondary maximum aggregation rate, the degree of enhancement, normality or suppression was determined, and the therapeutic effect was determined and monitored.
しかしながら、このような時間−凝集率曲線のパター
の分類或は凝集率レベルを基にした場合、血小板凝集に
直接相関させることができず、したがって判定に経験を
必要とし、判定結果が主観的になりがちであった。However, based on the classification of putters or aggregation level of such a time-aggregation rate curve, it is not possible to directly correlate with platelet aggregation, and therefore, the determination requires experience and the determination result is subjectively determined. It tended to be.
よって、本発明は、客観的に血小板の凝集能を判定可
能にする方法、装置並びに判定具を提供することを目的
とする。Therefore, it is an object of the present invention to provide a method, an apparatus and a determination tool that allow objective determination of platelet aggregation ability.
本発明は、この目的を達成するための方法として、血
液から分離されて血小板凝集惹起剤を添加された多血小
板血漿の時間経過に対する時間−凝集率曲線を複数段階
の血小板凝集惹起剤濃度についてそれぞれ作成し、これ
らの複数種類の時間−凝集率曲線から、前記血小板凝集
惹起剤に対する反応終了後の共通の基準時点の凝集率を
それぞれ求め、これらの凝集率を血小板凝集惹起剤濃度
に対してそれぞれプロットすることにより凝集惹起剤濃
度−凝集率曲線を作成し、この凝集惹起剤濃度−凝集率
曲線のパターンを基に凝集惹起剤濃度の変化に対してど
のようなパターンで凝集率が変化するかにより凝集能を
判定する。The present invention, as a method for achieving this object, a time-aggregation rate curve for the time course of platelet-rich plasma separated from blood and added with a platelet aggregation-inducing agent, for each of a plurality of stages of platelet aggregation-inducing agent concentration. Created, from these multiple types of time-aggregation rate curve, the aggregation rate at the common reference time point after the end of the reaction to the platelet aggregation-inducing agent was obtained, and these aggregation rates were calculated for the platelet aggregation-inducing agent concentration, respectively. An agglutination inducer concentration-aggregation rate curve was created by plotting, and based on the pattern of this agglutination inducer concentration-aggregation rate curve, the pattern in which the agglutination rate changes in response to changes in the agglutination inducer concentration The aggregating ability is determined by.
この際、判定精度を一層向上させるために、凝集惹起
剤濃度−凝集率曲線を、基準時点の凝集率までの時間−
凝集率曲線の面積を演算し、それぞれの面積値を血小板
凝集惹起剤濃度に対してプロットして作成することも考
えられる。At this time, in order to further improve the determination accuracy, the concentration-inducing agent concentration-aggregation rate curve is shown as the time to the aggregation rate at the reference time-
It is also possible to calculate the area of the aggregation rate curve and plot each area value against the platelet aggregation inducer concentration.
凝集惹起剤濃度−凝集率曲線のパターンを素早く、か
つ正確に判定するために、透明板に、横軸を血小板凝集
惹起剤濃度そして縦軸を凝集率とし、凝集の抑制、正常
及び亢進に対する標準的な凝集惹起剤濃度−凝集率曲線
をそれぞれ描記してある血小板凝集能判定用定規又は記
録紙を用いると好都合である。Aggregation-inducing agent concentration-To determine the pattern of the aggregation rate curve quickly and accurately, on a transparent plate, the horizontal axis is the platelet aggregation-inducing agent concentration and the vertical axis is the aggregation rate, which is a standard for inhibition of aggregation, normality and enhancement. It is convenient to use a ruler or a recording paper for determining the platelet aggregating ability in which the respective concentration-inducing agent concentration-aggregation rate curves are drawn.
本発明の方法による凝集惹起剤濃度−凝集率曲線を自
動的に作成する装置として、血液から分離されて血小板
凝集惹起剤を添加された多血小板血漿を撹拌しつつ透光
して、その受光量より凝集度を測定する光電式の血小板
凝集度測定手段と、この測定手段の検出信号から多血小
板血漿の時間経過に対する時間−凝集率曲線を作成する
凝集率曲線作成手段と、血小板凝集惹起剤の複数の濃度
段階に対する凝集率曲線データについて血小板凝集惹起
剤に対する反応終了後の共通の基準時点の凝集率をそれ
ぞれ求めて、これらの凝集率を血小板凝集惹起剤濃度に
対してプロットすることにより凝集惹起剤濃度−凝集率
曲線を作成する凝集惹起剤濃度−凝集率曲線作成手段
と、この曲線作成手段で作成された凝集惹起剤濃度−凝
集率曲線を表示もしくはプリントアウトする出力装置と
より構成する。As an apparatus for automatically creating an aggregation-inducing agent concentration-aggregation rate curve according to the method of the present invention, the platelet-rich plasma separated from blood and added with the platelet aggregation-inducing agent is transmitted while being stirred, and the amount of light received A photoelectric type platelet aggregation measuring means for measuring the degree of aggregation more, and an aggregation rate curve creating means for creating a time-aggregation rate curve with respect to the passage of time of platelet-rich plasma from the detection signal of this measuring means, and a platelet aggregation inducer Agglutination rate curve data for a plurality of concentration steps were calculated by determining the aggregation rates at the common reference time points after the reaction to the platelet aggregation inducer and plotting these aggregation rates against the platelet aggregation inducer concentration. A concentration-inducing agent concentration-aggregation rate curve producing means for producing an agent concentration-aggregation rate curve and an aggregation-inducing agent concentration-aggregation rate curve produced by this curve producing means are not displayed. More configuration and output device for printing out.
血液から分離されて血小板凝集惹起剤を添加され、か
つ撹拌されている多血小板血漿は、時間経過と共に添加
剤の特性に対応して凝集現象が進行する。したがって、
複数段階に凝集惹起剤の濃度を変えると、時間経過に対
して逐次凝集率をプロットした複数の時間−凝集率曲線
が得られる。この曲線データを基に反応が終了した基準
時点での凝集率値を凝集惹起剤の濃度変化に対してプロ
ットすると、惹起剤濃度−凝集率曲線が得られる。した
がって、この曲線データを基に凝集濃度変化に対して如
何なるパターンで凝集率が変化するかが判定できる。ま
た、実験的に２次凝集の出現し始める濃度（凝集閾値）
は、最大凝集率の50％程度に相当する濃度であることが
確認されており、したがって凝集閾値も直ちに判定でき
る。つまり、凝集が正常であるか否か、亢進もしくは抑
制の程度が直ちに判定できる。この判定に際して、血小
板凝集能判定用定規を当てるか、又は血小板凝集能判定
用記録紙にプロットして判定することもできる。The platelet-rich plasma that has been separated from the blood, to which the platelet aggregation-inducing agent has been added, and that has been agitated, undergoes an aggregation phenomenon over time in accordance with the characteristics of the additive. Therefore,
When the concentration of the aggregation-inducing agent is changed in a plurality of steps, a plurality of time-aggregation rate curves in which the agglutination rate is plotted sequentially with respect to time can be obtained. When the aggregation rate value at the reference time point when the reaction is completed is plotted against the change in the concentration of the aggregation inducer based on this curve data, an inducer concentration-aggregation rate curve is obtained. Therefore, based on this curve data, it is possible to determine what pattern the agglutination rate changes with respect to the agglomeration concentration change. In addition, the concentration at which secondary aggregation begins to appear experimentally (aggregation threshold)
Is confirmed to be a concentration corresponding to about 50% of the maximum aggregation rate, and therefore the aggregation threshold can be immediately determined. That is, whether or not the aggregation is normal and the degree of enhancement or suppression can be immediately determined. At the time of this determination, a ruler for determining the platelet aggregability may be applied, or it may be plotted on a recording paper for determining the platelet aggregability to make the determination.
本発明の装置によれば、凝集惹起剤濃度−凝集率曲線
が自動的に作成され、特に基準時点凝集率までの凝集率
曲線の面積を演算し、それぞれの面積値データとしての
凝集惹起剤濃度−凝集率曲線も自動的に作成するこもで
きる。According to the apparatus of the present invention, the aggregation inducer concentration-aggregation rate curve is automatically created, and in particular, the area of the aggregation rate curve up to the reference point aggregation rate is calculated, and the aggregation inducer concentration as each area value data. -The aggregation rate curve can also be created automatically.
本発明の血小板凝集能判定方法の実施例について説明
する。An example of the platelet aggregation ability determination method of the present invention will be described.
採集した血液から分離された多血小板血漿（PRP）に
血小板凝集惹起剤例えばADP（Adenosine Di−Phosphat
e）を例えば３段階1.0μＭ（モル）、2.0μＭ、4.0μＭ
の濃度で添加し、第１図に示すように、PRPの時間経過
に対する凝集率曲線を測定する。この際、PRPへのADPの
添加により血小板は１次凝集を行い、ADPの刺激により
血小板が活性化されると、放出反応が起こり、内因性AD
Pにより新たな２次凝集がおこり、適当量のADPで１次及
び２次凝集を共に観察することができる。つまり、ADP
1.0μＭによる凝集は凝集塊がほぼ完全に解離した１次
凝集解離型、2.0μＭによる凝集は二相性の凝集が出現
し凝集塊の解離が起こらない１次、２次凝集型、4.0μ
Ｍによる凝集は初期凝集に続いて凝集が起こり、１次と
区別ができない２次凝集である非解離型凝集、内因性AD
Pによる凝集を呈している。A platelet aggregation inducer such as ADP (Adenosine Di-Phosphat) is added to platelet-rich plasma (PRP) separated from the collected blood.
e) is, for example, three steps 1.0 μM (mol), 2.0 μM, 4.0 μM
The concentration of PRP is added, and the aggregation rate curve of PRP with time is measured as shown in FIG. At this time, platelets undergo primary aggregation by the addition of ADP to PRP, and when the platelets are activated by the stimulation of ADP, a release reaction occurs and endogenous AD
P causes new secondary aggregation, and both primary and secondary aggregation can be observed with an appropriate amount of ADP. That is, ADP
Aggregation by 1.0 μM is a primary aggregation dissociation type in which aggregates are almost completely dissociated, and aggregation by 2.0 μM is primary / secondary aggregation type in which disaggregation of aggregates does not occur due to the appearance of biphasic aggregation.
Aggregation by M occurs after initial aggregation and is secondary aggregation that is indistinguishable from primary aggregation. Non-dissociative aggregation, endogenous AD
It shows aggregation by P.
これらの３種類の時間−凝集率曲線に対して、前述の
各種の反応が終了してほぼ平衡状態になって例えば測定
開始後５分の基準時点の凝集率をそれぞれ求め、このよ
うな５分値を第２図に示すように、ADR濃度に対してプ
ロットして惹起剤濃度−凝集率曲線を作成する。そし
て、この曲線パターンから、予め実験的に作成してある
標準曲線と対比して正常状態と直ちに判定される。For these three types of time-aggregation rate curves, the agglutination rate at the reference time point, for example, 5 minutes after the start of measurement after the various reactions described above are completed and the state of equilibrium is almost reached, is obtained. As shown in FIG. 2, the values are plotted against the ADR concentration to prepare an inducer concentration-aggregation rate curve. Then, from this curve pattern, a normal state is immediately determined by comparison with a standard curve that has been experimentally created in advance.
また、最大凝集率はほぼ80％程度であることが分り、
したがって凝集閾値はその1/2の40％に対応する1.7μＭ
程度であることが分る。尚、濃度段階をさらに増やす
と、対応してより多種類の時間−凝集率曲線が得られ、
一層精密な惹起剤濃度−凝集率曲線が得られる。Also, it was found that the maximum aggregation rate is about 80%,
Therefore, the aggregation threshold is 1.7 μM, which corresponds to 40% of 1/2.
It turns out to be a degree. Incidentally, if the concentration steps are further increased, correspondingly more time-aggregation rate curves are obtained,
A more precise inducer concentration-aggregation rate curve is obtained.
このような判定に際して、第３図に示す透明の定規１
を用いると、前述のプロットした凝集惹起剤濃度−凝集
率曲線がいずれのタイプに属するかもしくは凝集閾値が
直ちに分る。この定規は、多数の健常者、強度亢進患
者、亢進患者、軽度亢進患者、抑制患者について例えば
８段階濃度のADPに対する本発明による方法で作成した
標準的な凝集惹起剤濃度−凝集率曲線を、横軸をADP濃
度そして縦軸を凝集率として、下表のように分類して描
記してある。尚、同一凝集惹起剤であってもその溶液等
で曲線がずれる可能性があり、点線は所属タイプのバラ
ツキ範囲を示す。In making such a judgment, the transparent ruler 1 shown in FIG.
Is used, it is possible to immediately know which type the above-mentioned plotted concentration-inducing agent concentration-aggregation rate curve belongs to or the aggregation threshold. This ruler is a standard aggregation-inducing agent concentration-aggregation rate curve prepared by the method according to the present invention with respect to, for example, eight-step concentration of ADP for a large number of healthy subjects, patients with increased strength, patients with increase, patients with slight increase, patients with suppression, The horizontal axis is the ADP concentration and the vertical axis is the agglutination rate, which are classified and plotted as shown in the table below. Even with the same aggregating agent, there is a possibility that the curve may shift due to the solution or the like, and the dotted line shows the variation range of the belonging type.
つまり、この使用の際、第３図に示す標準曲線が×印
で示す第２図のプロット点に重なり、Ｉ型と直ちに判定
され、同時に定規の目盛上で凝集閾値も分る。また、こ
のようなプロットを、第３図の標準の凝集惹起剤濃度−
凝集率曲線を印刷した血小板凝集能判定用記録紙上で行
っても同様に判定が正確、かつ直ちに行われる。さら
に、第３図で印で示すデータは、同様にADPを０、0.
5、1.0、1.5、2.0、2.5、3.0、4.0μＭの８段階の濃度
のデータに定規１を当てた場合であり、より明確にIII
型と判定される。 That is, in this use, the standard curve shown in FIG. 3 overlaps the plot points shown in FIG. 2 indicated by X, and it is immediately determined to be type I, and at the same time, the aggregation threshold is also known on the scale of the ruler. In addition, such a plot is used as the standard concentration-inducing agent concentration of FIG.
Even if it is performed on the recording paper for determining the platelet aggregation ability on which the agglutination rate curve is printed, the determination can be performed accurately and immediately. Furthermore, the data shown by the marks in FIG. 3 similarly show ADP of 0,0.
This is the case when the ruler 1 is applied to the data of the eight-step concentration of 5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0 μM, and more clearly III
It is determined to be a type.
尚、凝集惹起剤の種類によっては、５分値でなく、３
分値或は10分値等の別の基準時点のプロット或いは対応
した標準パターンの作成が必要である。Depending on the type of aggregating agent, the value is not 5 minutes, but 3
It is necessary to plot another reference time point such as a minute value or a ten minute value or create a corresponding standard pattern.
第４図は本発明の方法を実施する血小板凝集能判定装
置例の構成を示す。FIG. 4 shows the construction of an example of a platelet aggregation ability determination apparatus for carrying out the method of the present invention.
同図において、10は光電式の凝集度測定手段であり、
周知のように、血液から分離されて血小板凝集惹起剤を
添加されたPRPを採取したキャペット11を保温槽14にセ
ットしてスタラ12で撹拌し、その一方側から光源13で光
照射し、その透光を受光素子13aに入射させるように構
成されている。In the figure, 10 is a photoelectric type cohesion degree measuring means,
As is well known, the cappet 11 obtained by collecting the PRP separated from the blood and adding the platelet aggregation inducer is set in the heat-retaining tank 14 and stirred with the stirrer 12, and the light source 13 irradiates the light from one side thereof. The light transmission is configured to be incident on the light receiving element 13a.
受光素子13aは、周知のように、PRPをスタラ12にセッ
トしたときに０％、乏血小板血漿（PPP）をセットした
ときに100％の透光凝集値に対応するレベルの検知信号
を出力するように調整されている。As is well known, the light receiving element 13a outputs a detection signal of a level corresponding to a translucent aggregation value of 0% when PRP is set in the stirrer 12 and 100% when platelet poor plasma (PPP) is set. Is adjusted.
20は時間−凝集率曲線作成手段であり、受光素子13a
の検出信号により、PRPの時間経過に対する凝集率曲線
を作成する。21は凝集惹起剤濃度−凝集率曲線作成手段
であり、複数段階の濃度の時間−凝集率曲線について凝
集惹起剤の特性に対応して有意な凝集が惹起される時間
を経過した共通の基準時点の凝集率をそれぞれ求めて、
これらの凝集率データから凝集惹起剤濃度に対する凝集
率をプロットした凝集率曲線を作成する。22は例えば第
２図に示す標準パターンをメモリ22aに記憶しておき、
この標準パターンと測定した凝集惹起剤濃度−凝集率曲
線とを照合していずれの型もしくは凝集閾値かを判断す
る凝集率曲線照合手段である。これらの回路手段20、2
1、22は、CPUより構成することができる。23は、前述の
回路手段22、23で作成された凝集惹起剤濃度−凝集率曲
線を、この曲線パターンの特定されたタイプもしくは凝
集閾値と共に記録するプリンタである。Reference numeral 20 denotes a time-aggregation rate curve creating means, which is the light receiving element 13a.
An agglutination rate curve over time of PRP is created by the detection signal of. 21 is a means for creating an aggregation inducer concentration-aggregation rate curve, which is a common reference time point after a lapse of time in which significant aggregation is induced corresponding to the characteristics of the aggregation inducer with respect to the time-aggregation rate curve of multiple levels of concentration. Obtain the aggregation rate of
From these agglutination rate data, an agglutination rate curve is prepared by plotting the agglutination rate against the agglutination inducer concentration. 22 stores, for example, the standard pattern shown in FIG. 2 in the memory 22a,
This is an agglutination rate curve collating means for collating this standard pattern with the measured aggregation inducer concentration-aggregation rate curve to determine which type or aggregation threshold value. These circuit means 20, 2
1, 22 can be composed of a CPU. Reference numeral 23 is a printer for recording the concentration inducer concentration-aggregation rate curve created by the above-mentioned circuit means 22, 23 together with the specified type of the curve pattern or the aggregation threshold.
このような装置により、凝集度測定手段10において濃
度を変える都度キュペット11をセットし直して、複数種
類のPRPについて光電測定を行い、したがって時間−凝
集率曲線作成手段20がその都度複数種類のPRP凝集率曲
線を作成すると共に、凝集惹起剤濃度−凝集率曲線作成
手段21がそれぞれの基準時点の凝集率から一本の凝集惹
起剤濃度−凝集率曲線を作成し、被検者の血小板の凝集
能データプリンタ23に自動的に出力する。この際、プリ
ンタの記録紙を第３図に示すような標準パターンを印刷
されたものとし、その位置と同期状態で測定データを描
記されてもよい。With such a device, the cuppet 11 is reset every time the concentration is changed in the agglutination measuring means 10, and photoelectric measurement is carried out for a plurality of types of PRP. Therefore, the time-aggregation rate curve creating means 20 makes a plurality of types of PRP each time. Along with creating the agglutination rate curve, the aggregating agent concentration-aggregation rate curve creating means 21 creates a single aggregating agent concentration-aggregation rate curve from the agglutination rate at each reference time point, and agglutination of the platelets of the subject. It is automatically output to the data printer 23. At this time, the recording paper of the printer may be printed with a standard pattern as shown in FIG. 3, and the measurement data may be drawn in synchronization with the position.
凝集惹起剤濃度−凝集率曲線作成手段21は、基準時点
の凝集率値までの時間−凝集率曲線の面積を演算し、そ
れぞれの面積値をプロットするように構成すると、基準
時点の凝集率値自体でなく、その面積値による凝集惹起
剤濃度−凝集率曲線が容易に作成され、判定曲線間の弁
別が一層明確に行われる。Aggregation-inducing agent concentration-aggregation rate curve creating means 21 calculates the area of the time-aggregation rate curve up to the aggregation rate value at the reference time point, and when configured to plot each area value, the aggregation rate value at the reference time point The aggregation-inducing agent concentration-aggregation rate curve based on the area value, not by itself, is easily created, and the determination curves are more clearly discriminated.
以上、請求項１の発明によれば、判定対象となるデー
タが血小板の凝集能の感受性を直観させ得る１本の有意
義な曲線となるために、判定を直接的、かつ能率的に行
うことができ、そのパターンから血小板の凝集能が客観
的・高精度・高信頼度下で判定される。また、凝集の抑
制、正常及び亢進に対する定量的な判定として、２次凝
集が惹起され始める凝集惹起剤の濃度である凝集閾値も
最大凝集率に対する一定比率の凝集率の濃度を読取って
容易に推定される。請求項２の発明により、凝集惹起剤
濃度−凝集曲線を、基準時点の凝集率までの時間−凝集
率曲線の面積を演算し、それぞれの面積値を血小板凝集
惹起剤濃度に対してプロットして作成すると、判定精度
が一層向上する。As described above, according to the invention of claim 1, since the data to be determined is one meaningful curve that can intuitively infer the sensitivity of the aggregating ability of platelets, the determination can be performed directly and efficiently. The pattern can be used to objectively determine the aggregating ability of platelets with high accuracy and high reliability. In addition, as a quantitative determination of inhibition, normality, and enhancement of aggregation, the aggregation threshold, which is the concentration of the aggregation-inducing agent at which secondary aggregation begins to occur, can be easily estimated by reading the concentration of a certain ratio of the maximum aggregation ratio. To be done. According to the invention of claim 2, the area of the aggregation-inducing agent concentration-aggregation curve is calculated by calculating the area of the time-aggregation rate curve up to the aggregation rate at the standard time point, and plotting each area value against the platelet aggregation-inducing agent concentration. When created, the determination accuracy is further improved.
請求項３又は４の発明により、判定の際、凝集の抑
制、正常及び亢進に対する標準的な凝集惹起剤濃度−凝
集率曲線を描記してある血小板凝集能判定用定規又は記
録紙を用いると、極めて能率で、正確になる。According to the invention of claim 3 or 4, when a determination is made using a ruler or recording paper for determining a platelet aggregation ability, which depicts a standard aggregation inducer concentration-aggregation rate curve for inhibition, normality and enhancement of aggregation, Extremely efficient and accurate.
請求項４又は５の発明によれば、請求項１又は２の発
明による方法を実施するために凝集惹起剤濃度−凝集率
曲線を自動的に作成する装置が実現される。According to the invention of claim 4 or 5, an apparatus for automatically creating an aggregation inducer concentration-aggregation rate curve for carrying out the method according to the invention of claim 1 or 2 is realized.
第１図は本発明の血小板凝集能判定方法の実施例による
多血小板血漿の時間−凝集率曲線を示す図、第２図は同
実施例によるADR濃度に対する凝集率の５分値をプロッ
トした凝集惹起剤濃度−凝集率曲線を示す図、第３図は
同実施例による凝集惹起剤濃度−凝集率曲線の判定に用
いる血小板凝集能判定用定規を示す図、第４図は本発明
の実施例による血小板凝集能判定装置の構成を示す図及
び第５図は従来の判定方法を説明する多血小板血漿の時
間経過に対する典型的な凝集率曲線を示す図である。 １……判定定規FIG. 1 is a diagram showing a time-aggregation rate curve of platelet-rich plasma according to an example of the method for determining the platelet aggregation ability of the present invention, and FIG. 2 is an aggregation plotting the 5-minute value of the aggregation rate against the ADR concentration according to the example. FIG. 3 is a diagram showing an inducer concentration-aggregation rate curve, FIG. 3 is a diagram showing a ruler for determining platelet aggregation ability used for determination of the aggregation inducer concentration-aggregation rate curve in the same Example, and FIG. 4 is an example of the present invention. FIG. 5 and FIG. 5 showing a configuration of a platelet aggregation determining apparatus according to the present invention are diagrams showing a typical aggregation rate curve of a platelet-rich plasma with respect to time, for explaining a conventional determination method. 1 ... Judgment ruler
Claims (6)
加された多血小板血漿の時間経過に対する時間−凝集率
曲線を複数段階の血小板凝集惹起剤濃度についてそれぞ
れ作成し、 これらの複数種類の時間−凝集率曲線から、前記血小板
凝集惹起剤に対する反応終了後の共通の基準時点の凝集
率をそれぞれ求め、 これらの凝集率を血小板凝集惹起剤濃度に対してそれぞ
れプロットすることにより凝集惹起剤濃度−凝集率曲線
を作成し、 この凝集惹起剤濃度−凝集率曲線のパターンを基に凝集
惹起剤濃度の変化に対してどのようなパターンで凝集率
が変化するかにより凝集能を判定することを特徴とする
血小板凝集能判定方法。1. A time-aggregation rate curve for a time course of platelet-rich plasma separated from blood and added with a platelet aggregation-inducing agent is prepared for each of a plurality of levels of platelet aggregation-inducing agent concentration. From the aggregation rate curve, the aggregation rates at the common reference time points after the end of the reaction with the platelet aggregation-inducing agent are obtained, and the aggregation rates are plotted against the platelet aggregation-inducing agent concentration to obtain the concentration of the aggregation-inducing agent- An agglutination rate curve is created, and the agglutination ability is determined based on the pattern of the agglutination inducer concentration-aggregation rate curve and the pattern in which the agglutination rate changes in response to changes in the agglutination inducer concentration. And a method for determining platelet aggregation ability.
血小板凝集惹起剤濃度に対してそれぞれプロットするの
に代えて、血小板凝集惹起剤濃度に対して、基準時点の
凝集率までの時間−凝集率曲線の面積を演算し、それぞ
れの面積値をプロットして作成されることを特徴とする
請求項１に記載の血小板凝集能判定方法。2. An agglutination inducer concentration-aggregation rate curve is plotted instead of plotting the agglutination rate against the platelet agglutination inducer concentration, respectively. The platelet aggregation ability determination method according to claim 1, which is created by calculating the area of the time-aggregation rate curve and plotting the respective area values.
方法における凝集惹起剤濃度−凝集率曲線のパターンを
判定するための血小板凝集能判定用定規であって、 透明板に、横軸を血小板凝集惹起剤濃度そして縦軸を凝
集率とし、凝集の抑制、正常及び亢進に対する標準的な
凝集惹起剤濃度−凝集率曲線をそれぞれ描記してあるこ
とを特徴とする血小板凝集能判定用定規。3. A ruler for determining platelet aggregation ability for determining the pattern of the concentration-inducing agent concentration-aggregation rate curve in the method for determining platelet aggregation ability according to claim 1 or 2, comprising a transparent plate and a horizontal axis. Is a platelet aggregation-inducing agent concentration and the vertical axis is the agglutination rate, and a standard aggregation-inducing agent concentration-aggregation rate curve for inhibition, normality and enhancement of aggregation is depicted respectively, and a ruler for determining platelet aggregation ability is characterized. .
方法における凝集惹起剤濃度−凝集率曲線のパターンを
判定するための血小板凝集能判定記録紙であって、 凝集惹起剤濃度−凝集率曲線がプリントアウト又は手書
きされる用紙に、横軸を血小板凝集惹起剤濃度そして縦
軸を凝集率とし、凝集の抑制、正常及び亢進に対する標
準的な凝集惹起剤濃度−凝集率曲線をそれぞれ印刷して
あることを特徴とする血小板凝集能判定用記録紙。4. A platelet aggregation ability determination recording paper for determining a pattern of an aggregation inducer concentration-aggregation rate curve in the platelet aggregation ability determination method according to claim 1, wherein the aggregation inducer concentration-aggregation A standard curve of concentration-aggregation agent concentration-aggregation rate curve for inhibition, normality and acceleration of aggregation is printed on the paper on which the rate curve is printed out or handwritten, where the horizontal axis is the platelet aggregation inducer concentration and the vertical axis is the aggregation rate. A recording paper for determining platelet aggregation ability, which is characterized in that
加された多血小板血漿を撹拌しつつ透光して、その受光
量より凝集度を測定する光電式の血小板凝集度測定手段
と、 この測定手段の検出信号から多血小板血漿の時間経過に
対する時間−凝集率曲線を作成する凝集率曲線作成手段
と、 血小板凝集惹起剤の複数の濃度段階に対する凝集率曲線
データについて前記血小板凝集惹起剤に対する反応終了
後の共通の基準時点の凝集率をそれぞれ求めて、これら
の凝集率を血小板凝集惹起剤濃度に対してそれぞれプロ
ットすることにより凝集惹起剤濃度−凝集率曲線を作成
する凝集惹起剤濃度−凝集率曲線作成手段と、 この曲線作成手段で作成された凝集惹起剤濃度−凝集率
曲線を表示もしくはプリントアウトする出力装置とを備
えた、ことを特徴とする血小板凝集能判定装置。5. A photoelectric type platelet aggregation degree measuring means for transmitting the platelet-rich plasma separated from blood and added with a platelet aggregation inducer while stirring, and measuring the degree of aggregation from the amount of received light. Aggregation rate curve creating means for creating a time-aggregation rate curve for the time course of platelet-rich plasma from the detection signal of the measuring means, and aggregation rate curve data for a plurality of concentration steps of the platelet aggregation inducer, the reaction to the platelet aggregation inducer After obtaining the aggregation rate at the common reference time point after completion, plotting these aggregation rates against the platelet aggregation inducer concentration respectively creates an aggregation inducer concentration-aggregation rate curve Aggregation inducer concentration-aggregation A rate curve creating means and an output device for displaying or printing out the aggregation inducer concentration-aggregation rate curve created by this curve creating means are provided. Platelet aggregation determination device to.
凝集率を血小板凝集惹起剤濃度に対してそれぞれプロッ
トするのに代えて、血小板凝集惹起剤濃度に対して、基
準時点の凝集率までの時間−凝集率曲線の面積を演算
し、それぞれの面積値をプロットして凝集惹起剤濃度−
凝集率曲線を作成することを特徴とする請求項５に記載
の血小板凝集能判定装置。6. An aggregation inducer concentration-aggregation rate curve creating means comprises:
Instead of plotting the aggregation rate against the platelet aggregation-inducing agent concentration, the time-aggregation rate curve area up to the aggregation rate at the reference time point is calculated for the platelet aggregation-inducing agent concentration, and the area values of each are calculated. Is plotted and the concentration of aggregating agent-
The platelet aggregation ability determination device according to claim 5, wherein an aggregation rate curve is created.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1139615A JPH0810226B2 (en) | 1989-06-01 | 1989-06-01 | Platelet aggregation determining method and device, and aggregation determining tool |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1139615A JPH0810226B2 (en) | 1989-06-01 | 1989-06-01 | Platelet aggregation determining method and device, and aggregation determining tool |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH034168A JPH034168A (en) | 1991-01-10 |
| JPH0810226B2 true JPH0810226B2 (en) | 1996-01-31 |
Family
ID=15249420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1139615A Expired - Lifetime JPH0810226B2 (en) | 1989-06-01 | 1989-06-01 | Platelet aggregation determining method and device, and aggregation determining tool |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0810226B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014098242A1 (en) | 2012-12-20 | 2014-06-26 | 藤森工業株式会社 | Method for comprehensive assessment of platelet aggregation |
| EP3754327A1 (en) | 2019-06-18 | 2020-12-23 | Sysmex Corporation | Specimen measurement method and specimen measurement apparatus |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7344187B2 (en) * | 2019-06-18 | 2023-09-13 | シスメックス株式会社 | Sample measurement method and sample measurement device |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61116658A (en) * | 1984-11-09 | 1986-06-04 | Toa Medical Electronics Co Ltd | Thrombocyte agglutinating capacity measuring apparatus |
| JPS61272655A (en) * | 1985-05-28 | 1986-12-02 | Iryo Kogaku Kenkyusho:Kk | Quantitative discrimination method for platelet agglutination power |
-
1989
- 1989-06-01 JP JP1139615A patent/JPH0810226B2/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014098242A1 (en) | 2012-12-20 | 2014-06-26 | 藤森工業株式会社 | Method for comprehensive assessment of platelet aggregation |
| EP3754327A1 (en) | 2019-06-18 | 2020-12-23 | Sysmex Corporation | Specimen measurement method and specimen measurement apparatus |
| JP2020204558A (en) * | 2019-06-18 | 2020-12-24 | シスメックス株式会社 | Specimen measurement method and specimen measurement apparatus |
| US12247993B2 (en) | 2019-06-18 | 2025-03-11 | Sysmex Corporation | Specimen platelet aggregation measurement method and specimen platelet aggregation measurement apparatus |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH034168A (en) | 1991-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0062272B1 (en) | Method and device for checking or measuring the thickness of material layers | |
| RU2012102899A (en) | SYSTEMS AND METHODS FOR DIABETES CONTROL | |
| JPH07151726A (en) | Electrochemical immunosensor system | |
| ATE265177T1 (en) | APPARATUS, COMPUTER SYSTEM AND COMPUTER PROGRAM FOR DETERMINING A CARDIOVASCULAR PARAMETER | |
| WO2022054819A1 (en) | Blood coagulation reaction analysis method | |
| JPH0810226B2 (en) | Platelet aggregation determining method and device, and aggregation determining tool | |
| US5019999A (en) | Immunoanalysis method for discriminating between antigen excess and antibody excess conditions | |
| US20160314264A1 (en) | Method and system for monitoring excrement data | |
| JP3315824B2 (en) | Optical indicator for measuring the activity of ions in a sample | |
| Connors | Advances in chemical and colorimetric methods | |
| JP2934653B2 (en) | Automatic analyzer | |
| Shemirani et al. | Preanalytical factors affecting the mean platelet volume: a review | |
| EP0062616A1 (en) | Method for studying blood coagulation and the aggregation of platelets in the blood, and device employed to carry out said method | |
| Birks et al. | Energy Dispersion for Quantitative X-Ray Spectrochemical Analysis. | |
| Szundi et al. | Two intermediates appear on the lumirhodopsin time scale after rhodopsin photoexcitation | |
| JPH0315749A (en) | Method and apparatus for analyzing metal cleaning liquid | |
| JPS5928252B2 (en) | Method for detecting coagulation state of blood, etc. | |
| CN109959656A (en) | A kind of iodine concentration automatic testing method, equipment and system | |
| JPH0621854B2 (en) | Sedimentation velocity measuring device | |
| JPS63247644A (en) | Method for measuring immune reaction | |
| Smith | A kinetic experiment using potentiometric determination of reactant concentration | |
| JP2005043352A (en) | Immune reaction measuring method and immune reaction measuring apparatus | |
| SU1099075A1 (en) | Method of determining alkali and acid content in rock containing accessory maghemite | |
| JPS6332345A (en) | Analysis of grain size distribution | |
| Birnbaum | On the one-mediator null hypothesis of salary equity. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080131 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090131 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100131 Year of fee payment: 14 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100131 Year of fee payment: 14 |